MonTa Biosciences is a clinical stage biotech company located in the science park of The Danish Technical University in Kgs. Lyngby, North of Copenhagen.
Our technology is a novel cancer immunotherapy approach using micelles to stimulate immune cells to migrate into tumor tissue leading to tumor cell killing within hours. The micelles contain a small molecule TLR7 agonist that due to the micellar formulation show a novel approach to stimulate both innate and adaptive immune responses to suppress tumor growth and metastatic disease.
MonTa Biosciences started our clinical phase I study in solid tumor patients in 2021 and plan to complete the study in 2024.